The use of telaprevir for the treatment of hepatitis C in patients undergoing liver transplantation (Literature review and clinical experience)
Abstract
Authors reviewed published data concerning antiviral treatment of liver transplant recipients with 1st generation HCV protease inhibitors (telaprevir and boceprevir). Efficacy and adverse events have been analyzed with peculiar attention to drug-drug interactions between calcineurin inhibitors and HCV protease inhibitors. The article is illustrated with clinical cases.
About the Authors
M. Sh. Khubutiya
N.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare Department
Russian Federation
Russian Federation
V. E. Syutkin
N.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare Department
Russian Federation
Russian Federation
N. I. Geyvandova
Stavropol State Medical University
Russian Federation
Russian Federation
A. A. Salienko
N.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare Department
Russian Federation
Russian Federation
T. V. Gudzovskaya
Stavropol Regional Clinical Hospital
Russian Federation
Russian Federation
M. S. Novruzbekov
N.V. Sklifosovsky Research Institute for Emergency Medicine of Moscow Healthcare Department
Russian Federation
Russian Federation
References
1. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database / M. Charlton, K. Ruppert, S.H. Belle, et al. // Liver Transpl.– 2004. – Vol. 10, N.9. – P. 1120–1130.
2. Berenguer M. Hepatitis C virus-associated cholestatic hepatitis: we cannot seem to agree on diagnostic criteria / M. Berenguer, G. Mccaughan // Liver Transpl. – 2013. – Vol. 19, N.2. – P. 115– 117.
3. Interferon-based combination antiviral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis / C.S. Wang, H.H. Ko, E.M. Yoshida, et al. // Am. J. Transplant. – 2006. – Vol. 6, N.7. – P. 1586– 1599.
4. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies / E. Xirouchakis, C. Triantos, P. Manousou, et al. // J. Viral. Hepat. – 2008. – Vol. 15, N.10. – P. 699– 709.
5. Berenguer, M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin / M. Berenguer // J. Hepatol. – 2008. – Vol. 49, N.2. – P. 274–287.
6. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation / S. Pungpapong, B.A. Aqel, L. Koning, et al. // Liver Transpl. – 2013. – Vol. 19, N.7. – P. 690–700.
7. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience / A. Coilly, B. Roche, J. Dumortier, et al. // J. Hepatol. – 2014. – Vol. 60, N.1. – P. 78–86.
8. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data / C.R. Werner, D.P. Egetemeyr, U.M. Lauer, et al. // Liver Transpl. – 2012. – Vol. 18, N.12. – P. 1464–1470.
9. A multicenter study of protease inhibitortriple therapy in HCV-infected liver transplant recipients: report from the CRUSH-C Group / E. Verna, J. Burton, J. O’leary [et al.] // Abstracts of the 48th Annual Meeting of the European Association for the Study of the Liver. – 2013.
10. Amsterdam, The Netherlands. – Abst. 25.
11. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials / N. Chalasani, C. Manzarbeitia, P. Ferenci, et al. // Hepatol. – 2005. – Vol. 41, N.2. – P. 289–298.
12. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study / D. Samuel, T. Bizollon, C. Feray, et al. // Gastroenterol. – 2003. – Vol. 124, N.3. – P. 642–650.
13. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus / V. Garg, R. Van Heeswijk, J.E. Lee, et al. // Hepatol. – 2011. – Vol. 54, N.1. – P. 20–27.
14. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers / E. Hulskotte, S. Gupta, F. Xuan, et al. // Hepatol. – 2012. – Vol. 56, N.5. – P. 1622–1630.
15. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20- CUPIC) – NCT01514890 / C. Hezode, H. Fontaine, C. Dorival, et al. // J. Hepatol.– 2013. – Vol. 59, N.3. – P. 434–441.
16. Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis / G. Dultz, M. Seelhof, E. Herrmann, et al. // PloS one. – 2013. – Vol. 8, N.8. – E71262.
Review
For citations:
Khubutiya M.Sh., Syutkin V.E., Geyvandova N.I., Salienko A.A., Gudzovskaya T.V., Novruzbekov M.S. The use of telaprevir for the treatment of hepatitis C in patients undergoing liver transplantation (Literature review and clinical experience). Transplantologiya. The Russian Journal of Transplantation. 2015;(1):13-22.
Views:
688
Email this article 